Abstract

Protein–protein interactions have become attractive targets for both experimental and therapeutic interventions. The PSD-95/Dlg1/ZO-1 (PDZ) domain is found in a large family of eukaryotic scaffold proteins that plays important roles in intracellular trafficking and localization of many target proteins. Here, we seek inhibitors of the PDZ protein that facilitates post-endocytic degradation of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR): the CFTR-associated ligand (CAL). We develop and validate biochemical screens and identify methyl-3,4-dephostatin (MD) and its analog ethyl-3,4-dephostatin (ED) as CAL PDZ inhibitors. Depending on conditions, MD can bind either covalently or non-covalently. Crystallographic and NMR data confirm that MD attacks a pocket at a site distinct from the canonical peptide-binding groove, and suggests an allosteric connection between target residue Cys319 and the conserved Leu291 in the GLGI motif. MD and ED thus appear to represent the first examples of small-molecule allosteric regulation of PDZ:peptide affinity. Their mechanism of action may exploit the known conformational plasticity of the PDZ domains and suggests that allosteric modulation may represent a strategy for targeting of this family of protein–protein binding modules.

Document Type

Article

Publication Date

7-6-2018

Notes/Citation Information

Published in Bioscience Reports, v. 38, issue 4, BSR20180231, p. 1-16.

© 2018 The Author(s).

This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).

A correction to this article is available as the additional file listed below and online at: https://doi.org/10.1042/BSR20180231_COR

Digital Object Identifier (DOI)

https://doi.org/10.1042/BSR20180231

Funding Information

This work was supported by the National Institutes of Health [grant numbers R01-DK101541, P20-GM113132, R21-NS067613, T32-GM008704, P30-GM106394, P30-DK117469]; the Cystic Fibrosis Foundation [grant number STANTO15R0]; the Neukom CompX award; the American Lebanese Syrian Associated Charities (ALSAC); the St. Jude Children’s Research Hospital; beamline access was supported in part by the NIH [grant numbers GM-0080, P41-GM111244, P41-GM103393]; and the DOE [grant numbers DE-SC0012704, DE-AC02-76SF00515].

bsr20180231_Supp1.pdf (1093 kB)
Supplementary Figures

BSR20180231_COR.full.pdf (88 kB)
Correction

Share

COinS